Abstract: Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome, is one of the most common chronic liver diseases, which may progress to fibrosis, cirrhosis and hepatocellular carcinoma. NAFLD is characterized by the accumulation of lipids in the liver arising from multiple factors: increased fatty acid uptake, increased de novo lipogenesis, reduced fatty acid oxidation and very low density lipoproteins (VLDL) secretion. Most therapeutic approaches for this disease are often directed at reducing body mass index and improving insulin resistance through lifestyle modifications, bariatric surgery and pharmacological treatments. Nevertheless, there is increasing evidence that the use of natural compounds, as polyphenols, exert multiple benefits on the disorders associated with NAFLD. These molecules seem to be able to regulate the expression of genes mainly involved in de novo lipogenesis and fatty acid oxidation, which contributes to their lipid-lowering effect in the liver. Their antioxidant, anti-inflammatory, antifibrogenic and antilipogenic properties seem to confer on them a great potential as strategy for preventing NAFLD progression. In this review, we summarized the effects of these compounds, especially flavonoids, and their mechanisms of action, that have been reported in several studies carried out in in vitro and in vivo models of NAFLD.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in Western countries and its worldwide prevalence rate ranges from 6% to 35%, with a median of 20% [1] .
It is considered the hepatic manifestation of the metabolic syndrome [2] , ranging from simple steatosis to non-alcoholic steatohepatitis, liver fibrosis, cirrhosis and hepatocellular carcinoma [3] . About 10-20% of patients who have fatty liver develop inflammation and fibrosis, probably as consequence of a failure of antilipotoxic protection; nevertheless, inflammation may precede steatosis. In both situations, many parallel hits derived from extrahepatic tissues may promote liver inflammation and contribute to its progression to fibrosis and tumor development [4] . The best known risk factors for NAFLD are obesity, hyperglycemia, insulin resistance and hypertriglyceridemia [5] .
NAFLD is characterized by the accumulation of lipids in the liver that stems from multiple factors.
Thus, the increased fatty acid uptake as a result of the enhancement of the lipolysis from the adipocytes or the increased intake of dietary fat could contribute to this phenomenon. Additionally, increased de novo lipogenesis as well as reduced fatty acid oxidation and very low density lipoproteins (VLDL) secretion contribute to triglyceride accumulation in the liver [6] . However, this accumulation of triglycerides in the form of droplets within the hepatocytes may be protective whereas free fatty acids can serve as substrates for the formation of nontriglyceride lipotoxic metabolites that could cause actually the liver injury [7] .
As it is represented in Fig. 1 , the main proteins implicated in fatty acid uptake and trafficking are caveolins, fatty acid transport proteins (FATPs), fatty acid translocase (FAT) CD36 and fatty acid binding proteins (FABPs) [6, 8] . A complex network of nuclear receptors regulates enzymes, such as fatty acid synthase (FAS), involved in different steps of hepatic de novo lipogenesis [9] . It is worth mentioning liver X receptor (LXR), sterol regulatory element binding protein (SREBP)-1c, peroxisome proliferator activated receptor (PPAR)γ or carbohydrate responsive element binding protein (ChREBP) [10, 11] .
PPARα plays a central role in promoting the expression of key enzymes of fatty acid oxidation such as carnitine palmitoyltransferase 1 (CPT1), medium-chain acyl-CoA dehydrogenase (MCAD) or acyl-CoA oxidase (ACO) [12] . Finally, the microsomal triglyceride transfer protein (MTP) regulates triglyceride secretion through VLDL formation [13] . enzymes levels and hepatic lipid homeostasis, and restore insulin signaling and glycometabolism in HFDinduced NAFLD. The mechanism underlying its beneficial effect could implicate the suppression of oxidative stress-mediated NAD + depletion by increasing nicotinamide phosphoribosyltransferase (NAMPT) expression and decreasing poly (ADP-ribose) polymerase-1 (PARP1), thereby promoting SIRT1-mediated AMP-activated protein kinase (AMPK) activation to inhibit mammalian target of rapamycin (mTOR) signaling; this in turn enhances nuclear lipin1 localization, increasing fatty acid oxidation and triglyceride secretion and suppressing lipogenesis in the liver [38] .
Kaempferol, a flavonoid present in several natural sources such as tea, beans, tomatoes, onions, leeks or apples, displays multiple beneficial effects in cardiovascular and nerve systems, and it has also been reported to suppress the lipid accumulation in macrophages through the modulation of the expression of genes implicated in fatty acid uptake such as FAT/CD36 [39] . In vitro studies in HepG2 with inducedlipid accumulation shows that kaempferol, at concentrations ranging from 50 to 150 µM, presents a high inhibitory effect on cellular triglyceride levels and produces a dose-dependent decrease of intracellular ROS [33] .
Isorhamnetin, an O-methylated flavonol aglycone, has been reported to show cardio-protective, antiadipogenic, anti-tumor and anti-inflammatory effects [40] [41] [42] [43] . This flavonol is very efficient in reducing triglyceride overaccumulation and ROS generation in vitro after oleic acid-induced hepatic steatosis [33] , and it has been suggested that the Ca 2+/ calmodulin-dependent protein kinase kinase-2 (CaMKK2)-mediated AMPK activation is involved in the mechanism underlying the beneficial effect of isorhamnetin in the liver [44] .
Tea, berries and other fruits and vegetables contain high concentration of myricetin. This molecule may have a protective effect against diet-induced obesity and insulin resistance partly by improving lipid profile and reducing serum proinflammatory cytokine levels, as well as ameliorating liver steatosis through the increase of fatty acid oxidation by PPARα upregulation and downregulation of SREBP-1 and SREBP-2 [45, 46] , also showing antioxidant and lipid-lowering effects in vitro [33] .
The flavonol galangin is the major component of Alpinia officinarum, widely used in traditional
Chinese medicine for the treatment of several conditions. The Alpinia officinarum extract is able to efficiently suppress the expressions of C/EBPα, FAS, SREBP-1 and PPARγ in the liver and adipose tissue of HFD-fed mice, contributing to its antiobesity effect [47] . Nevertheless, the use of galangin at doses ranging from 1 to 40 µM fails to diminish oleic acid-induced triglyceride accumulation in an in vitro model, displaying only a slight reduction of ROS overproduction [33] .
Flavones
Chrysin (5,7-di-OH-flavone) has been reported to be involved in various biological activities [48] [49] [50] ,
and it seems to activate PPARγ in macrophages [51] . This flavone could ameliorate HFD-induced liver steatosis and inflammation, reducing pro-inflammatory cytokines and inducing anti-inflammatory cytokines and adiponectin levels, via induction of anti-inflammatory M2 phenotype and inhibition of pro-inflammatory M1 phenotype of macrophages through PPARγ upregulation [52] . On the contrary, chrysin displays a lacking triglyceride-lowering effect and a pro-oxidant activity in vitro at concentrations of 1-15 µM [33] .
Apigenin (4',5,7-trihydroxyflavone) is a flavonoid found in many fruits and vegetables, being parsley and chamomile the most abundant sources. This flavone has been documented to present antiinflammatory [53, 54] and anticancer properties [55] [56] [57] . In spite of its gluconeogenic and lipogenic reduction-mediated antidiabetic capacity reported in human cells [58] , it does not seem to be able to reduce triglyceride overaccumulation in oleic acid-treated HepG2 cells, showing also a remarkable dosedependent induction of ROS levels at concentrations ranging from 10 to 125 µM [33] .
Luteolin (3',4',5,7,-tetrahydroxyflavone) is one of the most common polyphenolic flavonoids present in many edible plants such as carrots, peppers, celery, olive oil, peppermint, thyme, rosemary and oregano [59] . Similarly to apigenin, luteolin presents anti-inflammatory [60] and anticancer [61, 62] properties and a gluconeogenic and lipogenic reduction-mediated antidiabetic capacity in vitro [58] , but unlike apigenin, luteolin is able to reduce in vitro ROS production and triglyceride overaccumulation [33, 63] , probably through the downregulation of SREBP-1c and FAS gene expressions and the AMPK-mediated upregulation of CPT1 [63] .
Flavanones
Naringenin is a citrus-derived flavonoid, that has been reported to attenuate dyslipidemia and improve insulin resistance in addition to steatosis, by increasing hepatic fatty acid oxidation and preventing SREBP-1c-mediated lipogenesis in several in vivo models [64] . Nevertheless, its use in an in vitro model of oleic acid-induced hepatic steatosis fails to decrease triglyceride content and displays a pro-oxidant effect [33] .
Another flavonoid found abundantly in citrus fruits is hesperetin. This flavanone has shown antioxidant [65] , anti-inflammatory [66] , anticancer [67] , antiallergic [68] and neuroprotective [69] properties, but little is known about its effect on NAFLD models. A treatment with hesperetin in an in vitro model of hepatic steatosis could not reduce triglyceride increase and slightly suppressed intracellular ROS [33] .
The flavanone taxifolin shows a high antioxidant and antilipogenic effects in vitro, reducing the induced triglyceride overaccumulation [33] , an effect that could be mediated, at least in part, by its ability to inhibit diacylglycerol acyltransferase (DGAT) and FAS activities [70, 71] .
Flavanols
angiotensin-II (AT-II) and the suppression of angiotensin-converting enzyme (ACE) and AT-II type 1 receptor (AT-1R) expressions. EGCG also reduced inflammation, oxidative stress and lipid peroxidation, preventing NASH-related liver fibrosis and subsequent tumorigenesis as it was demonstrated by the inhibition of the development of hepatic premalignant lesions [72] . Transforming growth factor (TGF)/SMAD, phosphatidylinositol 3-kinase (PI3K)/AKT/forkhead box protein O1 (FOXO1) and NF-κB pathways could be also implicated in the beneficial effect of EGCG on fibrosis, oxidative stress and inflammation [73] . Moreover, EGCG plays a positive role in diminishing triglyceride levels in vitro at concentrations under 25 µM, but it reflects a negative effect at higher concentrations. As EGCG, the flavanols (+)-catechin and (-)-epicatechin display a triglyceride-lowering effect in the same in vitro model [33] .
The major active component of Flavangenol®, one of several pine bark extract products, is the procyanidin B1. This catechin is able to reduce palmitic acid-induce triglyceride accumulation in HepG2 cells by enhancing the β-oxidation of fatty acids through the gene expression upregulation of key enzymes involved in this process [74] .
Isoflavones
In vivo and in vitro studies about beneficial relation of isoflavones and NAFLD and adiposity have been summarized in a review of Kim and Kang [75] , putting special emphasis in the effect of these compounds via ChREBP and Wnt signaling.
One of the most prevalent isoflavones in soy is daidzein [76] . It has been reported that daidzein supplementation might alleviate HFD-induced NAFLD in mice by regulating de novo lipogenesis and improving insulin resistance, as well as modulating adipocyte metabolism. The mechanism underlying this effect could implicate LXRβ and ChREBP downregulation, fatty acid β-oxidation-related gene expression upregulation and the increase of leptin and adiponectin but the reduction of ghrelin levels [77] .
Daidzein is also documented to reduce in a dose-dependent manner both triglyceride and ROS levels in an in vitro model of oleic acid-induced steatosis [33] .
The use of puerarin, the major active component isolated from Pueraria lobata, is reported to show beneficial effects in several models of NAFLD. This isoflavone is able to diminish steatosis, inflammation and ballooning by reducing triglyceride and cholesterol levels and TNFα expression in the liver, and improving leptin signal transduction through janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathways [78] [79] [80] .
Another of most abundant isoflavones in soy is genistein [76] . Its use in in vitro [33] and in vivo [81, 82] 
Anthocyanidins
Cyanidin is an anthocyanidin commonly found in fruits and vegetables. The antioxidant enzyme activation through extracellular signal-regulated kinase (ERK) and JNK pathways and Nrf2 upregulation in addition to ameliorated cytotoxicity and the improvement of the perturbation of genes involved in lipid metabolism, could contribute to its beneficial effects on NASH [83] .
A glycoside of cyanidin, cyanidin-3-O-β-glucoside, is able to improve obesity and triglyceride metabolism in KKAy mice, reducing body and liver weights and fat pads, and hepatic and serum triglyceride content. These actions may be mediated by an increase in lipoprotein lipase (LPL) activity in plasma and skeletal muscle and inhibition of LPL in adipose tissue through the activation of AMPK [84] .
Furthermore, this anthocyanin decreases hepatic glycerol-3-phosphate acyltransferase 1 (GPAT1) activity and its translocation to the outer mitochondrial membrane, diminishing triglyceride synthesis and thereby attenuating hepatic steatosis [85] . In vitro studies show the hepatoprotective effect of cyanidin-3-O-β-glucoside against hyperglycemia-accelerated steatohepatitis in NAFLD, process mediated, at least in part, by the improvement of antioxidant status and the inhibition of the mitochondria-mediated apoptotic pathway through AKT activation and JNK inactivation [86] . This anthocyanin has been also used combined with others such as cyanidin-3-rutinoside and pelargonidin-3-glucoside, displaying a protective effect against diet-induced body weight gain [87] .
More recently, a further review about the effect of anthocyanins on hepatic lipid accumulation and lipotoxicity associated with NAFLD in both in vitro and in vivo models, has proposed the possible mechanism underlying the beneficial effects of anthocyanins, based on available studies. This includes the AMPK activation-mediated lipogenesis inhibition and lipolysis promotion by reducing SREBP-1c and inducing PPARα activity respectively, in addition to the reduction of oxidative stress by the induction of antioxidant enzymes [88] .
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Representative compounds of the major classes of flavonoids with known effects on NAFLD. 
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4-HNE, 4-hydroxy-2'-nonenal; ABC, ATP-binding; ACC, acetyl-CoA carboxylase; ACO, acyl-CoA oxidase; ALDH, aldehyde dehydrogenase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMPK, AMP-activated protein kinase; Apo, apolipoprotein; AREG, amphiregulin; ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; AST, aspartate aminotransferase; BMI, body mass index; C/EBPα, CCAAT/enhancer binding protein alpha; COL, collagen; COX-2, cyclooxygenase-2; CPT1, carnitine palmitoyltransferase 1; CTGF, connective tissue growth factor; CYP, cytochrome P450; ERK, extracellular signal-regulated kinase; FAS, fatty acid synthase; FAT/CD36, fatty acid translocase CD36; FDFT1, farnesyl-diphosphate farnesyltransferase 1; FFA, free fatty acid; FNTA, farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha; GPAM, glycerol-3-phosphate acyltransferase 1 mitochondrial; GPx, glutathione peroxidase; GSH, glutathione; HDL, high density lipoprotein; HFD, high fat diet; HMGB1, high-mobility group box 1 protein; HO-1, heme oxygenase-1; HOMA-IR, homeostasis model assessment for insulin resistance; HSP, heat shock protein; IKKβ, inhibitor κB kinase β; IL, interleukin; iNOS, inducible nitric oxide synthase; IκBα, inhibitor of NF-κB alpha; JNK, c-Jun terminal kinase; LDH, lactate dehydrogenase; LDL, low density lipoprotein; LXRα, liver X receptor alpha; M, morin; MCD, methionine and choline deficient; MDA, malondialdehyde; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; My, myricetin; NAMPT, nicotinamide phosphoribosyltransferase; NAS, NAFLD activity score; NF-κB, nuclear factor kappa B; NLRP3, NOD-like receptor family, pyrin domain-containing 3; Nrf2, nuclear factor (erythroid-derived 2)-related factor-2; PARP, poly (ADP-ribose) polymerase; PDGFB, platelet-derived growth factor subunit B; PGC1α, PPARγ coactivador-1 alpha; PLOD3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3; PON1, paraoxonase 1; PPARα, peroxisome proliferator-activated receptor alpha; PPARδ, peroxisome proliferator-activated receptor delta; PPARγ, peroxisome proliferator-activated receptor gamma; Q, quercetin; R, rutin; Raptor, regulatory associated protein of mTOR; ROS, reactive oxygen species; SCD1, stearoyl-CoA desaturase-1; SIRT1, silent mating type information regulation 2 homolog1; SOD, superoxide dismutase; SREBP, sterol regulatory element-binding protein; TBARS, thiobarbituric acid-reactive substance; TG, triglyceride; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinases; TLR, toll-like receptor; TNFα, tumor necrosis factor alpha; Tx, troxerutin; TXNIP, thioredoxin-interacting protein; VCAM1, vascular cell adhesion protein 1; VLDL, very low density lipoprotein; XDH, xanthine dehydrogenase; XO, xanthine oxidase; α-SMA, alpha-smooth muscle actin; γGT, gamma glutamyl transferase; ↑, increase; ↓, decrease; --, no effect. 
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Genistein 1 mg/Kg b.w./day (60 days)
Wistar rats. High fructose diet-feeding (60 days)
Genistein 1, 2 and 4 g/Kg food (12 weeks) C57BL/6J mice. HFDfeeding (12 weeks) ↑Body weight (G↓) ↑Fat pads (G↓) NAFLD activity score; NF-κB, nuclear factor kappa B; P, puerarin; PAI-1, plasminogen activator inhibitor-1; PI3K, phosphatidylinositol 3-kinase; PKCζ, protein kinase C zeta; PPARγ, peroxisome proliferatoractivated receptor gamma; SOD, superoxide dismutase; STAT, signal transducer and activator of transcription; TBARS, thiobarbituric acid-reactive substance; TG, triglyceride; TGF, transforming growth factor; TIMP, tissue inhibitor of metalloproteinases; TNFα, tumor necrosis factor alpha; VLDL, very low density lipoprotein; α-SMA, alpha-smooth muscle actin; γGT, gamma glutamyl transferase; ↑, increase; ↓, decrease; --, no effect. GSSG, oxidized glutathione; HFD, high fat diet; IL, interleukin; IRS1, insulin receptor substrate 1; IRβ, insulin receptor beta; JNK, c-Jun terminal kinase; LDH, lactate dehydrogenase; MDA, malondialdehyde; MTP, microsomal triglyceride transfer protein; My, myricetin; N, naringenin; PARP, poly (ADP-ribose) polymerase; PPARα, peroxisome proliferator-activated receptor alpha; Q, quercetin; R, rutin; ROS, reactive oxygen species; SOD, superoxide dismutase; SREBP, sterol regulatory element-binding protein; TG, triglyceride; TNFα, tumor necrosis factor alpha; ↑, increase; ↓, decrease; --, no effect.
Silybum marianum, known as milk thistle, is a member of Asteraceae family that contains a mixture of flavonolignans named silymarin and two flavonoids (quercetin and taxifolin). Silymarin is a lipophilic extract composed of silybin A, silybin B, isosilybin A, isosilybin B, silychristin, silydianin and isosilychristin. Silibinin, a mixture of silybin A and silybin B, is the major constituent of silymarin. This mixture of flavonolignans displays a lipid-lowering effect in both in vitro and in vivo models of induced lipid accumulation [28, 89, 90] . It has been proven that silibinin administration counteracts the progression of liver injury in several nutritional models of NASH, by improving antioxidant status, insulin resistance, steatosis, ballooning and inflammation. This effect appears to be a consequence of the capacity of silibinin to reduce increased NF-κB activity and subsequent iNOS overexpression as well as ROS and reactive nitrogen species (RNS) levels. Moreover, the increased phosphorylation of JNK, which is associated with insulin resistance and inflammation, is attenuated by silibinin. Likewise, silbinin diminishes DNA damage and lipoperoxidation and increases SCD1 and FABP1 expressions, that are downregulated in NASH models [91] [92] [93] . SCD1 and FABP1 downregulation is associated with cell sensitization to saturated fatty acid-induced death [94] and lipotoxicity [95] , respectively. Silymarin also displays antifibrogenic effects through the downregulation of TGFβ [96] , one of the critical cytokines involved in fibrogenesis, and the suppression of hepatic stellate cells activation and α 1 -procollagen production, although it can not completely block the histological appearance of liver fibrosis. Moreover, the increase in nuclear translocation of Nrf2, that may upregulate many antioxidant genes, might contribute to the antioxidant capacity of silymarin besides the reduction of TNFα expression, probably by reversing ERK activation [97] . On the contrary, non-effect of silymarin has been shown on phosphorylation levels of ERK, showing in addition an anti-apoptotic activity by lowering activation of procaspase-3 to active caspase-3 [96] . Silymarin has also been reported to display positive effects in patients with NAFLD [98, 99] , in which the efficacy of this extract may be more readily observed compared with patients with hepatitis C, because of their higher plasma flavonolignan concentrations and more extensive enterohepatic cycling [100] . Combination of silibinin with phospholipids appears to increase its bioavailability [101] . Several clinical studies evidence the efficacy of silibinin combined with phospholipids and vitamin E in patients with NAFLD, who exhibit improvements in aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma glutamyl transferase (γGT) levels, insulin resistance and liver histology in addition to the normalization of the cholestasis and cholesterol levels [102] [103] [104] [105] .
Curcumin is a polyphenol derived from Curcuma longa (turmeric), a food spice and colouring agent widely utilized in Indian and other South Asia countries. Its use in in vivo models of NASH reveals an improvement of steatosis, inflammation, ballooning and fibrosis, and a reduction of blood serum monocyte chemoattractant protein (MCP)-1, TNFα and IL-6 levels. Lipoperoxidation is attenuated, the antioxidant status is enhanced, and the expressions of NF-κB, suppressor of cytokine signaling 3 (SOCS3), SREBP-1c, FAS, ACC and 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase are decreased in the liver after curcumin treatment [80, 106, 107] . The beneficial effects of curcumin on steatosis and inflammation could be mediated by the STAT3 signaling activation and the improvement of mitochondrial function [107] . In vitro studies show that curcumin is able to reduce induced lipid accumulation by downregulating lipogenic proteins and upregulating the expression of fatty acid β-oxidation-related genes as PPARα, via AMPK phosphorylation [108] . Moreover, this polyphenol seems to protect hepatocytes from lipoapoptosis [109] and iron-induced insulin resistance and oxidative stress in cells treated with stearic acid, probably reducing phosphorylated JNK levels [110] .
Resveratrol (trans-3,4',5-trihydroxystilbene) is a polyphenol abundantly present in red wine and, to a lesser extent, in other foods such as grapes or nuts. This compound reduces body weight in obese mice, enhances antioxidant enzymes levels and diminishes lipoperoxidation, improving also serum lipid profile and hepatic steatosis through the increase of SIRT1 expression and phosphorylation levels of AMPK, and FOXO1, and promoting FOXO1 translocation from the nucleus to the cytoplasm [111] . Hepatoprotective actions of resveratrol and the mechanisms responsible of these beneficial effects, observed in in vitro and in vivo studies, have been recently reviewed [112] . A polyphenol extract also obtained from red wine is
Provinol™, that contains proanthocyanidols, prodelphinidol, anthocyanins, catechin, resveratrol and others. This extract could help to prevent steatosis through SIRT1upregulation and subsequent AMPK and PPARγ coactivador (PGC) 1α increased expressions, leading to an enhanced fatty acid β-oxidation [113] . On the other hand, wine stored in oak barrels improves its organoleptic properties, including better taste. Indeed, many bioactives polyphenols contained in red wine derive from oak during the maturation.
Oak bark extract treatment in a NAFLD model in rats displays multiple benefits, such as the reduction of body weight and abdominal fat pads, the improvement of insulin resistance, serum lipid profile and liver histology, as well as the recovery of cardiovascular structure and function [114] .
Theaflavin is the major polyphenol derived from black tea, the most widely consumed tea in the world. Its use in a mouse model of fatty liver resulted in a decrease of hepatic steatosis, oxidative stress, inflammation and apoptosis, contributing to its protective effect against ischemia-reperfusion injury [115] . Green tea contents a high amount of catechins as EGCG, whose beneficial properties on NAFLD have been summarized herein. Several studies in murine models show the protective effect of green tea against induced non-alcoholic steatohepatitis [116, 117] . Likewise it has been reported an improved liver function and fatty liver status in patients with NAFLD after consuming green tea with high-density catechins for 12 weeks [118] . Previously, it had been published a further review about therapeutic There are many other species of plants proven to present preventive effects on NAFLD. Thus,
Taraxacum officinale (dandelion) shows properties similar to black soybean, as it has been observed in murine models of NAFLD a significant reduction of hepatic lipid accumulation, body and liver weights and serum cholesterol, triglyceride, insulin and glucose levels, with an improved insulin resistance by AMPK pathway activation, after dandelion leaf extract treatment [123, 124] . Myrcia bella is a species belonging to the Myrtaceae family whose principle constituents are phenolic acids and flavonoids, such as quercetin and myricetin. The extract of leaves of this species presents hypoglycemic activity, probably due to the activation of the insulin signaling pathway involving PI3K/AKT proteins that leads in turn to the store and prevention of the degradation of glucose in the liver. Moreover, the extract can act as a hypolipidemic agent by reducing the levels of serum lipids [125] . In the same way, the effect of and ACC was reduced and levels of pAMPKα, ACO1 and PPARα were increased in flavonoids-treated rats, reverting the effect of HFD. This led to a fatty acid synthesis downregulation and a fatty acid β-oxidation promotion with a subsequent lipid content reduction in hepatocytes [90] . Phyllanthus urinaria, a traditional medicinal plant, with a high amount of tannins and flavonoids, has also been documented to ameliorate the severity of steatohepatitis in in vitro and in vivo nutritional models. This effect seems to be attributed to the suppression of CYP2E1-mediated oxidative stress and JNK and NF-κB pathwaysmediated inflammatory response, in addition to the induction of fatty acid oxidation through CYP4A10 upregulation and the suppression of lipogenic transcription factor C/EBPβ [126] . Likewise, Ilex hainanensis Merr., whose major bioactive components are chlorogenic acid, kaempferol-7-O-β-Dglucoside and ilexgenin A [127] , displays preventive effects on hepatic induced steatosis by alleviating insulin resistance and regulating lipid metabolism, inflammation and oxidative stress, through the regulation of PPARα and CYP2E1 expressions [128, 129] . The lipid-lowering effect of Ginkgo biloba, whose principle active ingredients are quercetin, kaempferol and isorhamnetin, seems to be attributed to the content of these flavonoids, through the CPT1A-mediated fatty acid oxidation enhancement [130, 131] . Furthermore, there are several traditional Chinese medicine formulas, as Salvia-Nelumbinis naturalis or Hugan Qingzhi tablet, with a lipid-lowering effect on induced steatosis, via enhancing hepatic insulin sensitivity and fatty acid oxidation or reducing lipogenesis [132, 133] .
Flavangenol®, one of several pine bark extract products, is also reported to exert a lipid-lowering action in the liver of mice with insulin resistance, abnormalities of carbohydrate and lipid metabolism, hypertension and a marked fatty liver, by increasing the expression of fatty acid oxidation-related genes.
The effect of Flavangenol® could be attributed in part to procyanidin B1, its major bioactive component [74] . Other authors explain the beneficial effects of total flavonoids from citrus on NASH in mice fed with a HFD by the modulation of the SIRT1/PGC-1α signal pathway, which might in turn be related to the improvement of oxidative stress and lipid peroxidation [134] . Polyphenols from pomegranate flowers seem to improve also insulin resistance and steatosis in rats with diabetes and non-alcoholic fat liver disease, probably by enhancing PON1 expression in the liver [135] . In the same way, polyphenolic extracts obtained from blueberries [136, 137] , mulberries [137] and bayberries [138] show preventive effects on NAFLD, inhibiting body weight gain, decreasing serum cholesterol, reducing insulin resistance and attenuating lipid accumulation, as well as improving plasma antioxidant status and inhibiting the inflammatory and apoptotic responses. Likewise, polyphenolic extract from lotus root, the edible rhizome of Nelumbo nucifera, rich in proanthocyanidins, alleviates hepatic steatosis by suppressing lipogenic enzymes activities [139] .
CONCLUSION
Polyphenols, as flavonoids and many other related natural compounds, display beneficial effects on NAFLD, preventing multiple disorders associated with the disease. These molecules possess the ability to modulate the expression of several genes whose deregulation contributes to lipid accumulation, fibrosis, inflammation, oxidative stress or insulin resistance. Their lipid-lowering effects seem to be associated with their capacity to regulate the expression of genes mainly involved in de novo lipogenesis and fatty acid β-oxidation, although the antioxidant and anti-inflammatory properties of these compounds might also contribute to this capacity (Fig. 3) . Overall, in view of results obtained in in vitro and in vivo models, as well as in patients with NAFLD, it may be concluded that the use of flavonoids and other natural substances should be considered as therapy for preventing NAFLD progression. 
